Research
Hormonal
Targeting obesity with GLP-1-based therapies reduces major adverse cardiovascular events (MACE) in patients with established atherosclerotic cardiovascular disease (ASCVD) and overweight/obesity, even without diabetes.
If you have heart disease and are overweight or obese, even without diabetes, treating your obesity with semaglutide (2.4 mg weekly) can significantly lower your risk of heart attack, stroke, or cardiovascular death by 20%. This treatment addresses the root metabolic driver of your cardiovascular risk.
StrongSupportsVERY_HIGH confidence
subcutaneous semaglutide 2.4 mg once weekly significantly reduced the incidence of major adverse cardiovascular events (MACE)... by 20% compared to placebo (HR 0.80; 95% CI, 0.72-0.90; p<0.001).
Why this rating
Based on a large, randomized, placebo-controlled cardiovascular outcomes trial (SELECT) with 17,604 patients.
Source
iCARDIO Alliance Global Implementation Guidelines for the Management of Obesity 2025
Stefan D. Anker et al. · International Journal of Cardiovascular Sciences · 2026
clinical_guideline
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →